Cargando…

VEGF-C as a putative therapeutic target in cancer

Detalles Bibliográficos
Autores principales:	Michaelsen, Signe R., Poulsen, Hans S., Hamerlik, Petra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592284/ https://www.ncbi.nlm.nih.gov/pubmed/31258839 http://dx.doi.org/10.18632/oncotarget.27007

Ejemplares similares

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro
por: Staberg, Mikkel, et al.
Publicado: (2016)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM2B
por: Staberg, Mikkel, et al.
Publicado: (2018)

Is VEGF a new therapeutic target for hypertension in chronic kidney disease?
por: Kim, Yon Su
Publicado: (2013)

Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study
por: Nørøxe, Dorte S., et al.
Publicado: (2020)

Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study
por: Nørøxe, Dorte Schou, et al.
Publicado: (2019)

(18)F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PlGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma
por: Nedergaard, Mette Kjoelhede, et al.
Publicado: (2015)

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
por: Urup, Thomas, et al.
Publicado: (2017)

Growth factor restriction impedes progression of wound healing following cataract surgery: identification of VEGF as a putative therapeutic target
por: Eldred, Julie A., et al.
Publicado: (2016)

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
por: Stewart, Michael W
Publicado: (2012)

Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2018)

Putative growth characteristics of micrometastatic breast cancer
por: Chambers, Ann F, et al.
Publicado: (2008)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

Anti-VEGF and Beyond
por: Bertelmann, T., et al.
Publicado: (2017)

Purinergic Pathways in the Spinal Microglia as a Putative Target for Treatment of Chronic Abdominal Pain
por: Bercik, Premysl
Publicado: (2022)

Corrigendum: Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2019)

Extracranial metastases in glioblastoma—Two case stories
por: Schou Nørøxe, Dorte, et al.
Publicado: (2018)

Novel Therapeutic Targets in Cancers
por: Levantini, Elena
Publicado: (2023)

Cancer Metastasis: A Therapeutic Target
por: Rajendran, Peramaiyan, et al.
Publicado: (2019)

Cell autonomous Vegf-C/Vegfr3 signaling in adult neural stem cells
por: Kang, Tae Hyuk, et al.
Publicado: (2015)

Expounding newer vistas in VEGF
por: Natarajan, Sundaram
Publicado: (2013)

VEGF-mTOR signaling links obesity and endometrial cancer
por: Sahoo, Subhransu S., et al.
Publicado: (2018)

Sclerostin as a Putative Myokine in Sarcopenia
por: Yi, Hyon-Seung
Publicado: (2022)

Identification of a putative new therapeutical target for Hodgkin's lymphoma
por: Kewitz, Stefanie, et al.
Publicado: (2015)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Targeting Neuropilin-1 to Inhibit VEGF Signaling in Cancer: Comparison of Therapeutic Approaches
por: Gabhann, Feilim Mac, et al.
Publicado: (2006)

Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution
por: Michaelsen, Signe Regner, et al.
Publicado: (2013)

Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma
por: Frandsen, Simone, et al.
Publicado: (2019)

DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas
por: Michaelsen, Signe Regner, et al.
Publicado: (2018)

Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications
por: Campbell, Kevin T., et al.
Publicado: (2017)

Phosphoglycerate Dehydrogenase: Potential Therapeutic Target and Putative Metabolic Oncogene
por: Zogg, Cheryl K.
Publicado: (2014)

Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma
por: Kristensen, Lasse S., et al.
Publicado: (2016)

Pathogenesis and New Therapeutic Targets of Ovarian Cancer
por: Shih, Ie-Ming, et al.
Publicado: (2012)

Molecular markers as therapeutic targets in lung cancer
por: Tseng, Hsin-Hui, et al.
Publicado: (2013)

Common therapeutic target for both cancer and obesity
por: Chang, Yie-Hwa
Publicado: (2017)

Novel Therapeutic Targets for Tumor Microenvironment in Cancer
por: Bei, Roberto, et al.
Publicado: (2023)

The Use of Longitudinal (18)F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts
por: Nedergaard, Mette K., et al.
Publicado: (2014)

Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion
por: Shin, Ye Ji, et al.
Publicado: (2022)

Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer
por: Voutsadakis, Ioannis A.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jd6j6cii5nultlec2jidr2c93n